Back to mobile site

Piper Sandler on Abivax (ABVX): 'Obefazimod's Differentiated Profile Reinforced by UEGW Data'

October 21, 2026 8:45 AM EDT Send to a Friend
Piper Sandler analyst Allison M. Bratzel reiterated an Overweight rating and $175.00 price target on Abivax (NASDAQ: ABVX).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login